CQN-PHENOM
8.10.2021 04:02:09 CEST | Business Wire | Press release
Fourth paragraph, first sentence of release dated October 6, 2021, should read: As the vice president and general manager for Phenom in Central Europe, Gerstner will be responsible for strengthening existing and new customer relationships in Central Europe, including Germany, Austria, Switzerland, France and BENELUX (instead of in Germany, Austria and Switzerland).
The updated release reads:
PHENOM HIRES SENIOR LEADERS TO OVERSEE RAPID GROWTH IN EUROPE
Thomas Gerstner and Andy Joeres bring decades of experience scaling SaaS enterprises in EMEA
Phenom , the global leader in Talent Experience Management (TXM), today announced the hiring of two executives to drive the company’s surging global growth. Thomas Gerstner will lead Phenom’s business in Central Europe, and Andy Joeres will oversee initiatives in the United Kingdom and Ireland, Northern Europe, Middle East and Africa. The positions were created to continue building momentum in EMEA, where there has been an exploding demand for talent experience, AI and automation from HR teams.
Following numerous acquisitions and the addition of many enterprise customers in EMEA, Phenom’s headcount in Europe has quickly exceeded 100 employees. With operations in the United Kingdom, Ireland, Germany, Netherlands, France, Italy, Spain, Sweden, and Switzerland, Phenom expects to continue aggressively recruiting into 2022 across customer success, sales, account management, marketing, engineering, product and more.
“The need for AI-powered talent experiences is universal, and the interest in Phenom’s platform originating from EMEA is increasing every day,” said Mahe Bayireddi, co-founder and CEO of Phenom. “We’re thrilled that Andy and Thomas are joining our team. They carry proven track records of success meeting ambitious business objectives in many different markets around the world, and we expect their leadership will inspire our talented overseas team to bring amazing talent experiences to global enterprises.”
As the vice president and general manager for Phenom in Central Europe, Gerstner will be responsible for strengthening existing and new customer relationships in Central Europe, including Germany, Austria, Switzerland, France and BENELUX. In his last role, he was the EMEA president of Pathlock — defining, implementing, and executing growth strategy across all channels. For 14 years, Gerstner also held various senior executive roles at SAP, including senior vice president for the SuccessFactors business in the Middle and Eastern European region and managing director in Asia.
“Phenom is already turning heads in Central Europe, and it’s incredible to now be part of this special journey,” said Gerstner. “Organisations that have invested in AI-powered talent experiences are miles ahead of their competitors. Already in Central Europe, Phenom’s sophisticated platform is making a huge difference, helping organizations transform the way they acquire, develop and retain talent.”
Joeres will serve as Phenom’s vice president of sales for EMEA, where he will focus on bringing new business to the company. Joeres has managed the launch of hyper-growth initiatives for companies like Celonis and Snow, where he spearheaded triple-digit, year-over-year growth and exponentially scaled personnel from small teams to large units with deep impact across the enterprise.
“My passion has always been designing go-to-market strategies and then executing them for companies that have a clear, profound vision,” said Joeres. “HR teams are realizing that intelligent experiences are the present and future of hiring and retaining the best talent — and the Phenom TXM platform is the solution. AI and automation are now requirements for scaling those experiences. I look forward to championing Phenom’s platform to help organisations reduce cost and time to hire, while increasing employee retention.”
About Phenom
Phenom is a global HR technology company with a purpose to help a billion people find the right job. With an expertise in building AI-powered, scalable solutions, Phenom Talent Experience Management (TXM) personalizes and automates the talent journey for candidates, recruiters, employees and management with its Career Site, Chatbot, CRM, CMS, SMS and Email Campaigns, University Recruiting, Internal Mobility, Career Pathing, Diversity & Inclusion, Talent Marketplace, Gigs, Referrals, Hiring Manager and Analytics. As a result, employers improve their talent acquisition and talent management efforts by helping candidates and employees find the right job, recruiters identify and engage the right talent, and management optimizes HR strategy, process and spend. Phenom was ranked among the fastest-growing technology companies in the 2020 Deloitte Technology Fast 500, and won a regional 2020 Timmy Award for launching and optimizing HelpOneBillion.com.
Headquartered in Greater Philadelphia, Phenom also has offices in India, Israel, the Netherlands, Germany and the United Kingdom.
For more information, please visit www.phenom.com . Connect with Phenom on LinkedIn , Twitter , Facebook , YouTube and Instagram .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211006005383/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom